[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reactive-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reactive-arthritis":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100420181","testing-of-an-educational-tool-for-patients-with-melanoma-and-pre-existing-autoimmune-disease-who-are-candidates-for-immune-checkpoint-inhibitors-100420181",false,"NCT04751396","Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors","Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers","Inclusion Criteria:\n\n* Diagnosis of melanoma\n* Diagnosis of pre-existing autoimmune disease\n\n  * Inflammatory bowel disease\n\n    * Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist\n    * For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically\n    * Treatment with aminosalicylates, corticosteroids, thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists)\n  * Rheumatoid arthritis\n\n    * Diagnosis of rheumatoid arthritis by a rheumatologist\n    * Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy\n  * Systemic lupus erythematosus\n\n    * Diagnosis of systemic lupus erythematosus by a rheumatologist\n  * Psoriasis\n\n    * Diagnosis of psoriasis by a dermatologist\n    * Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies\n  * Spondyloarthropathies\n\n    * Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis\u002Fspondylitis by a rheumatologist\n    * Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy\n* Age of 18 years or older\n* Patients whose physicians had recommended they begin using any of the currently available immune checkpoint inhibitors or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor\n* E-mail access and computer with Internet access or telephone\n* Ability to communicate in English or Spanish\n* CLINICIAN\n* Prescribed immune checkpoint inhibitors\n* Are providing care for patients with melanoma\n* In the clinics at MD Anderson","ALL","18 Years",{"count":19,"type":20},125,"ESTIMATED","OBSERVATIONAL","This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.",[24,25,26,27,28,29,30,31,32,33,34,35,36],"Ankylosing Spondylitis","Autoimmune Disease","Crohn Disease","Enteropathic Arthritis","Enteropathic Spondylitis","Inflammatory Bowel Disease","Melanoma","Psoriasis","Psoriatic Arthritis","Reactive Arthritis","Rheumatoid Arthritis","Systemic Lupus Erythematosus","Ulcerative Colitis","RECRUITING","2026-05-18",{"date":40,"type":41},"2026-05-20","ACTUAL",{"date":43,"type":41},"2022-04-20",{"date":45,"type":20},"2027-02-02",{"name":47,"class":48},"M.D. Anderson Cancer Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":21,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":49},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).",true,"99 Years",{"count":59,"type":20},5000,"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[63,64,24,32,33,65,35,66,67,68,69,70,71,72,34,73,74,75,76,77],"Rheumatic Diseases","Adult Onset Still Disease","Antiphospholipid Syndrome","Behcet Disease","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Lyme Disease","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Sarcoidosis","Systemic Sclerosis","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":80,"type":41},"2026-02-13",{"date":82,"type":41},"2020-08-04",{"date":84,"type":20},"2030-06-01",{"name":86,"class":48},"Yale University"]